search
Back to results

Melatonin for Prevention of Postoperative Delirium After Lower Limb Fracture Surgery in Elderly Patients (DELIRLESS)

Primary Purpose

Orthopedic Surgery

Status
Recruiting
Phase
Phase 3
Locations
France
Study Type
Interventional
Intervention
Melatonin 4 mg
Placebo oral tablet
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Orthopedic Surgery focused on measuring delirium, aging, Perioperative neurocognitive disorders, melatonine, orthopedic surgery

Eligibility Criteria

70 Years - undefined (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Demographic criteria: patient 70 years old or older
  • Diagnostic criteria: isolated fracture of a lower limb

    • Proximal femoral fractures: head, cervical, or trochanteric fractures
    • Periprosthetic hip fracture
    • Femoral shaft fracture
    • Distal femoral fractures: supracondylar or condylar
    • Periprosthetic knee fracture
    • Tibial plateau fracture
  • Treatments/strategies/procedures: scheduled orthopedic surgery (osteosynthesis or arthroplasty)
  • proxy or care giver knowing baseline cognitive status of the patient present or reachable by phone for an interview

Exclusion Criteria:

  • Patient already taking Melatonin
  • Contraindications and precaution for use of Melatonin administration:

    • Hypersensitivity to the active substance or to any of the excipients of Circadin©
    • Liver failure (presence of some of the following clinical and biological symptoms: icterus, asterixis, ascites, known esophageal varices, total bilirubin >20 micromol/L, FV <70%),
    • Cirrhosis (known histological liver fibrosis)
    • Renal failure with clearance <30 ml/min O Autoimmune disease O Hereditary galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption syndrome
    • Patients taking fluvoxamine, 5- or 8-methoxypsoralen, cimetidine, oestrogenotherapy, quinolones, carbamazepine, rifampicin
  • Other concomitant trauma than lower limb fracture(s)
  • Surgery scheduled in more than 5 days
  • Patient under mechanical ventilation
  • Patient refusing to participate
  • Patient not talking / understanding French (delirium assessment impossible)
  • Patient under tutorship
  • Patient already participating to another interventional study
  • No signed informed consent,
  • No affiliation to a social security regime

Secondary Exclusion Criteria:

Secondary exclusion (before randomization): diagnosis of delirium at the CAM assessment at inclusion, or creatinin clearance <30 ml / min and /or biological signs of hepatocellular insufficiency (bilirubin> 20 umol/l and factor V <70%) if samples not available during the anesthesiologist consultation and so performed after inclusion.

Sites / Locations

  • hôpital BeaujonRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Experimental group

Control group

Arm Description

melatonin 4mg per os every night, starting the evening before surgery (or 2 hours before emergency surgery) and until day 5 after surgery

placebo of this drug with the same schedule, during the same period of time.

Outcomes

Primary Outcome Measures

Postoperative delirium incidence
The Confusion Assessment Method (CAM) score, for patients hospitalized in surgery, or CAM-ICU score, for patients hospitalized in ICU will be applied daily during the first 10 days after surgery or end of hospital stay if shorter

Secondary Outcome Measures

Number of days CAM positive
CAM will be applied daily during the first 10 days. the minimum 0 and maximum 4 values, and higher scores mean a worse outcome.
Incidence of postoperative sedative or antipsychotic drugs administration from
Daily review of the medical chart and prescriptions looking for any sedative or antipsychotic drug administration
Incidence of postoperative physical restrain prescription
Daily review of the medical chart and prescriptions looking for physical restraint prescription.
Incidence of postoperative falls
Daily review of the medical chart and prescriptions looking for falls, whichever the gravity
Mini Mental State Examination
Cognitive testing interview at bedside using the widely used French validated translation of the Mini Mental State Examination. the minimum 0 and maximum 30 values, and higher scores mean a better outcome.
Duration of hospital stay
Daily review of the medical file
30 days postoperative mortality
Phone call (or visit for those who had not left the hospital) to the patient or caregivers
30 days postoperative patient autonomy
Phone call (or visit for those who had not left the hospital) to the patient or caregivers and evaluation by the Katz Index of activities of daily living. The minimum and maximum values are respectively 0 and 6, and higher scores mean a better outcome.
30 days postoperative Quality of life
evaluated by EQ5D5L (standardized instrument for measuring generic health status : MOBILITY, SELF-CARE, USUAL ACTIVITIES, PAIN/DISCOMFORT and ANXIETY/ DEPRESSION),) Questionnaire. the minimum 5 and maximum 125 values, and higher scores mean a better outcome.
30 days postoperative QALYs (quality-adjusted life year)
QALYs (quality-adjusted life year) are the utility weights for the 30 day period x30/365. the minimum and maximum values are respectively 0 and1, and higher scores mean a better outcome.
Total hospital costs at 30 days
calculated as the cumulative costs of all admissions (in- and outpatient, home care, rehabilitation) over a 30 day period
Incremental cost effectiveness
The incremental cost effectiveness ratio is the difference in total costs divided by the difference in the incidence rate of delirium between the two arms
cost utility ratios
the incremental cost utility ratio is the difference in total costs divided by the difference in QALYs (quality-adjusted life year)
Occurrence of side effects
During the follow-up, daily interview of the patient and review of the medical chart will be performed, looking for side effects of melatonin.

Full Information

First Posted
February 28, 2020
Last Updated
May 24, 2023
Sponsor
Assistance Publique - Hôpitaux de Paris
search

1. Study Identification

Unique Protocol Identification Number
NCT04335968
Brief Title
Melatonin for Prevention of Postoperative Delirium After Lower Limb Fracture Surgery in Elderly Patients
Acronym
DELIRLESS
Official Title
Melatonin for Prevention of Postoperative Delirium After Lower Limb Fracture Surgery in Elderly Patients: a Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 23, 2021 (Actual)
Primary Completion Date
January 31, 2024 (Anticipated)
Study Completion Date
April 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Postoperative delirium (POD) is one of the most frequent complications after surgery in elderly patients, affecting between 20 and 40% of patients older than 60 after major surgery. This complication has huge consequences for the patients, families and society: increase of morbidity and mortality, prolonged length of stay, cognitive and functional decline leading to loss of autonomy, and important additional healthcare costs. Among numerous risk factors identified, perioperative inflammatory stress is a key element in delirium genesis: surgical trauma releases danger signals in systemic circulation, activating immune cells and leading to neuroinflammation. Melatonin is a neurohormone regulating circadian rhythm. But it also exhibits antioxidant and free radical scavenger properties, and regulates energy metabolism and immune function. It has already demonstrated a neuroprotective potential in various animal models. Its use against delirium is promising: it decreases delirium incidence in elderly patients hospitalized in medical ward, and several studies are now recruiting in ICU. The hypothesis of the trial is that in a high-risk population, perioperative melatonin can reduce the incidence of POD. The main objective is to evaluate the effect of perioperative melatonin administration on postoperative delirium incidence in the first 10 days after surgery, in elderly patients (over 70 years old) being hospitalized and scheduled for acute surgery of fractured lower limb (from femoral head to tibial plateau). This is a prospective, national multicentric (24 centers), phase III, superiority, comparative randomized (1:1) double-blinded clinical trial with two parallel arms: Experimental group: melatonin 4mg per os every night, starting the evening before surgery (or 2 hours before emergency surgery) and until day 5 after surgery. Control group: placebo of this drug with the same schedule, during the same period of time. The patients are aged 70 or older, hospitalized and scheduled for surgery of a severe fracture of a lower limb (from femoral head to tibial plateau).
Detailed Description
Postoperative delirium (POD) is one of the most frequent complications after surgery in elderly patients, affecting between 20 and 40% of patients older than 60 after major surgery. This complication has huge consequences for the patients, families and society: increase of morbidity and mortality, prolonged length of stay, cognitive and functional decline leading to loss of autonomy, and important additional healthcare costs. Among numerous risk factors identified, perioperative inflammatory stress is a key element in delirium genesis: surgical trauma releases danger signals in systemic circulation, activating immune cells and leading to neuroinflammation. In the brain, especially in hippocampus, proinflammatory cytokines, immune cells recruitment and microglial activation alter synaptic plasticity and lead to acute cognitive dysfunction. Moreover, with aging, an increase in initial neuroinflammatory response and a decrease in subsequent resolution phase are observed. Melatonin is a neurohormone regulating circadian rhythm. But it also exhibits antioxidant and free radical scavenger properties, and regulates energy metabolism and immune function. It has already demonstrated a neuroprotective potential in various animal models. Its use against delirium is promising: it decreases delirium incidence in elderly patients hospitalized in medical ward, and several studies are now recruiting in ICU. Concerning the perioperative period, only two studies with conflicting results are available. The first one (Sultan, 2010), that has shown that melatonin decreases POD incidence, has strong methodological limitations (no calculated sample size, only 53 patients in melatonin group, all patients, even in the control group received melatonin if they developed POD, etc). In the second one (deJonghe, 2014), melatonin had no effect on POD incidence, but showed a reduction in the proportion of patients with POD exceeding 2 days. These conflicting results emphasize the need for a third RCT, with optimized methodology. The hypothesis of the trial is that in a high-risk population, perioperative melatonin can reduce the incidence of POD. The main objective is to evaluate the effect of perioperative melatonin administration on postoperative delirium incidence in the first 10 days after surgery, in elderly patients (over 70 years old) being hospitalized and scheduled for acute surgery of fractured lower limb (from femoral head to tibial plateau). This is a prospective, national multicentric (24 centers), phase III, superiority, comparative randomized (1:1) double-blinded clinical trial with two parallel arms: Experimental group: melatonin 4mg per os every night, starting the evening before surgery (or 2 hours before emergency surgery) and until day 5 after surgery. Control group: placebo of this drug with the same schedule, during the same period of time. The patients are aged 70 or older, hospitalized and scheduled for surgery of a severe fracture of a lower limb (from femoral head to tibial plateau). An ancillary study is also planned in this study with the hypothesise that : Patients presenting post-operative delirium may exhibit significant perturbations of phenotypic and transcriptomic features of circulating leukocytes, of plasma levels of cytokines, and of oxidative stress level. Administration of melatonin may prevent these perturbations. Ancillary study concerns Beaujon, Bichat and la Pitié centers.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Orthopedic Surgery
Keywords
delirium, aging, Perioperative neurocognitive disorders, melatonine, orthopedic surgery

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Prospective, national multicentric (21 centers), phase III, superiority, comparative randomized (1:1) double-blinded clinical trial with two parallel arms
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
790 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Experimental group
Arm Type
Experimental
Arm Description
melatonin 4mg per os every night, starting the evening before surgery (or 2 hours before emergency surgery) and until day 5 after surgery
Arm Title
Control group
Arm Type
Placebo Comparator
Arm Description
placebo of this drug with the same schedule, during the same period of time.
Intervention Type
Drug
Intervention Name(s)
Melatonin 4 mg
Intervention Description
melatonin 4mg per os every night, starting the evening before surgery (or 2 hours before emergency surgery) and until day 5 after surgery.
Intervention Type
Drug
Intervention Name(s)
Placebo oral tablet
Intervention Description
placebo of this drug with the same schedule, during the same period of time.
Primary Outcome Measure Information:
Title
Postoperative delirium incidence
Description
The Confusion Assessment Method (CAM) score, for patients hospitalized in surgery, or CAM-ICU score, for patients hospitalized in ICU will be applied daily during the first 10 days after surgery or end of hospital stay if shorter
Time Frame
10 days after surgery
Secondary Outcome Measure Information:
Title
Number of days CAM positive
Description
CAM will be applied daily during the first 10 days. the minimum 0 and maximum 4 values, and higher scores mean a worse outcome.
Time Frame
10 days after surgery
Title
Incidence of postoperative sedative or antipsychotic drugs administration from
Description
Daily review of the medical chart and prescriptions looking for any sedative or antipsychotic drug administration
Time Frame
10 days after surgery
Title
Incidence of postoperative physical restrain prescription
Description
Daily review of the medical chart and prescriptions looking for physical restraint prescription.
Time Frame
10 days after surgery
Title
Incidence of postoperative falls
Description
Daily review of the medical chart and prescriptions looking for falls, whichever the gravity
Time Frame
10 days after surgery
Title
Mini Mental State Examination
Description
Cognitive testing interview at bedside using the widely used French validated translation of the Mini Mental State Examination. the minimum 0 and maximum 30 values, and higher scores mean a better outcome.
Time Frame
10 days (or end of hospital stay if shorter)
Title
Duration of hospital stay
Description
Daily review of the medical file
Time Frame
30 days after surgery
Title
30 days postoperative mortality
Description
Phone call (or visit for those who had not left the hospital) to the patient or caregivers
Time Frame
30 days after surgery
Title
30 days postoperative patient autonomy
Description
Phone call (or visit for those who had not left the hospital) to the patient or caregivers and evaluation by the Katz Index of activities of daily living. The minimum and maximum values are respectively 0 and 6, and higher scores mean a better outcome.
Time Frame
30 days after surgery
Title
30 days postoperative Quality of life
Description
evaluated by EQ5D5L (standardized instrument for measuring generic health status : MOBILITY, SELF-CARE, USUAL ACTIVITIES, PAIN/DISCOMFORT and ANXIETY/ DEPRESSION),) Questionnaire. the minimum 5 and maximum 125 values, and higher scores mean a better outcome.
Time Frame
30 days after surgery
Title
30 days postoperative QALYs (quality-adjusted life year)
Description
QALYs (quality-adjusted life year) are the utility weights for the 30 day period x30/365. the minimum and maximum values are respectively 0 and1, and higher scores mean a better outcome.
Time Frame
30 days after surgery
Title
Total hospital costs at 30 days
Description
calculated as the cumulative costs of all admissions (in- and outpatient, home care, rehabilitation) over a 30 day period
Time Frame
30 days after surgery
Title
Incremental cost effectiveness
Description
The incremental cost effectiveness ratio is the difference in total costs divided by the difference in the incidence rate of delirium between the two arms
Time Frame
30 days after surgery
Title
cost utility ratios
Description
the incremental cost utility ratio is the difference in total costs divided by the difference in QALYs (quality-adjusted life year)
Time Frame
30 days after surgery
Title
Occurrence of side effects
Description
During the follow-up, daily interview of the patient and review of the medical chart will be performed, looking for side effects of melatonin.
Time Frame
30 days after surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Demographic criteria: patient 70 years old or older Diagnostic criteria: isolated fracture of a lower limb Proximal femoral fractures: head, cervical, or trochanteric fractures Periprosthetic hip fracture Femoral shaft fracture Distal femoral fractures: supracondylar or condylar Periprosthetic knee fracture Tibial plateau fracture Treatments/strategies/procedures: scheduled orthopedic surgery (osteosynthesis or arthroplasty) proxy or care giver knowing baseline cognitive status of the patient present or reachable by phone for an interview Exclusion Criteria: Patient already taking Melatonin Contraindications and precaution for use of Melatonin administration: Hypersensitivity to the active substance or to any of the excipients of Circadin© Liver failure (presence of some of the following clinical and biological symptoms: icterus, asterixis, ascites, known esophageal varices, total bilirubin >20 micromol/L, FV <70%), Cirrhosis (known histological liver fibrosis) Renal failure with clearance <30 ml/min O Autoimmune disease O Hereditary galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption syndrome Patients taking fluvoxamine, 5- or 8-methoxypsoralen, cimetidine, oestrogenotherapy, quinolones, carbamazepine, rifampicin Other concomitant trauma than lower limb fracture(s) Surgery scheduled in more than 5 days Patient under mechanical ventilation Patient refusing to participate Patient not talking / understanding French (delirium assessment impossible) Patient already participating to another interventional study No signed informed consent, No affiliation to a social security regime Secondary Exclusion Criteria: Secondary exclusion (before randomization): diagnosis of delirium at the CAM assessment at inclusion, or creatinin clearance <30 ml / min and /or biological signs of hepatocellular insufficiency (bilirubin> 20 umol/l and factor V <70%) if samples not available during the anesthesiologist consultation and so performed after inclusion.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Stéphanie Sigaut
Phone
1 40 87 59 11
Ext
+33
Email
stephanie.sigaut@aphp.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Emmanuel Weiss
Phone
1 40 87 59 11
Ext
+33
Email
emmanuel.weiss@aphp.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stéphanie Sigaut
Organizational Affiliation
APHP
Official's Role
Principal Investigator
Facility Information:
Facility Name
hôpital Beaujon
City
Clichy-sous-Bois
ZIP/Postal Code
93390
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
stéphanie sigaut
Email
stephanie.sigaut@aphp.fr

12. IPD Sharing Statement

Citations:
PubMed Identifier
34952881
Citation
Sigaut S, Couffignal C, Esposito-Farese M, Degos V, Molliex S, Boddaert J, Raynaud-Simon A, Durand-Zaleski I, Marcault E, Jacota M, Dahmani S, Paugam-Burtz C, Weiss E. Melatonin for prevention of postoperative delirium after lower limb fracture surgery in elderly patients (DELIRLESS): study protocol for a multicentre randomised controlled trial. BMJ Open. 2021 Dec 24;11(12):e053908. doi: 10.1136/bmjopen-2021-053908.
Results Reference
derived

Learn more about this trial

Melatonin for Prevention of Postoperative Delirium After Lower Limb Fracture Surgery in Elderly Patients

We'll reach out to this number within 24 hrs